Abstract:
:Cancer immunotherapy has seen a tremendous number of failures and only few recent regulatory successes. This review is a first in a series dedicated to evaluate the status of current global clinical pipeline for cancer vaccines. Apart from specific areas of medical need which can be addressed by cancer vaccines, the analysis of the pipeline by clinical indication suggests that a disproportionately large number of candidates is currently developed in prostate, breast, lung cancer and melanoma with significant gap of candidates in remaining oncology indications. With potential offering and benefits that cancer immunotherapy could bring to patient community and society as a whole, we require new innovative R&D, improved Antigen Discovery programs and business models to fill serious gaps in cancer vaccine R&D pipeline.
journal_name
Hum Vaccin Immunotherjournal_title
Human vaccines & immunotherapeuticsauthors
Kudrin A,Hanna MG Jrdoi
10.4161/hv.20474subject
Has Abstractpub_date
2012-08-01 00:00:00pages
1135-40issue
8eissn
2164-5515issn
2164-554Xpii
20474journal_volume
8pub_type
杂志文章,评审abstract::The relationship between obesity and vaccine efficacy is a serious issue. Previous studies have shown that vaccine efficacy is lower in the obese than in the non-obese. Here, we examined the influence of obesity on the efficacy of influenza vaccination using high fat diet (HFD) and regular fat diet (RFD) mice that wer...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.4161/hv.28332
更新日期:2014-01-01 00:00:00
abstract::SARS-CoV-2, which causes coronavirus disease 2019 (COVID-19), is suspected to have been first contracted via animal-human interactions; it has further spread across the world by efficient human-to-human transmission. Recent reports of COVID-19 in companion animals (dogs and cats) and wild carnivores such as tigers hav...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章,评审
doi:10.1080/21645515.2020.1807802
更新日期:2020-12-01 00:00:00
abstract::Abrin, obtained from the seeds of Abrus precatorius plant, is a potent toxin belonging to the family of type II ribosome-inactivating proteins. Recently, a recombinant vaccine consisting of the A subunits of abrin and its homolog Abrus precatorius agglutinin (APA) was demonstrated to protect mice from abrin lethality....
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2015.1067741
更新日期:2016-01-01 00:00:00
abstract::Rotavirus (RV) infection is the primary cause for childhood gastroenteritis worldwide. In Korea, RV infection is most common among children less than 5 years of age. This post-licensure study was conducted to further evaluate the RV vaccine (RIX4414) to provide additional local clinical data to the Korean Food and Dru...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章,随机对照试验
doi:10.4161/hv.19853
更新日期:2012-06-01 00:00:00
abstract::Compared with the general population, patients with cancer in general are more susceptible to vaccine-preventable infections, either by an increased risk due to the malignancy itself or immunosuppressive treatment. The goal of immunizations in these patients is therefore to provide protection against these infections,...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章,评审
doi:10.1080/21645515.2015.1062189
更新日期:2015-01-01 00:00:00
abstract::Cancer vaccines are designed to stimulate the body's immune system to kill tumor cells. To improve their immunogenicity, vaccine antigens must be combined with adjuvants which are able to stimulate the innate immunity and potentiate the adaptive immune response. In the last years a new generation of adjuvants mimickin...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2017.1321725
更新日期:2017-08-03 00:00:00
abstract::Malaria has long been recognized as a public health problem. At the community level, vector control, and antimalarial medicines are the main means for reducing incidence, morbidity, and mortality of malaria. A vaccine not only would bring streamlining in the prevention of morbidity and mortality from malaria but also ...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.4161/hv.28482
更新日期:2014-01-01 00:00:00
abstract:BACKGROUND:To evaluate the validity and reliability of a survey to identify vaccine hesitancy among parents. METHODS:Cross-sectional survey of parents of 19-35 month old children was conducted in Changxing County, Zhejiang Province, through a questionnaire developed for the survey of the vaccine hesitancy. Construct v...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2019.1572409
更新日期:2019-01-01 00:00:00
abstract::Following the introduction of universal immunization against rotavirus, concerns were raised regarding pathogen-replacement of rotavirus by norovirus. The study aim was to examine the incidence and characteristics and norovirus gastroenteritis before and after the introduction of universal rotavirus immunization in Is...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2019.1599522
更新日期:2019-01-01 00:00:00
abstract::The objective of this study was to find common immune mechanism across different kinds of vaccines. A meta-analysis of microarray datasets was performed using publicly available microarray Gene Expression Omnibus (GEO) and Array Express data sets of vaccination records. Seven studies (out of 35) were selected for this...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章,meta分析
doi:10.1080/21645515.2015.1008884
更新日期:2015-01-01 00:00:00
abstract:UNLABELLED:In adults with a tetanus-prone injury, combined vaccines such as Tdap-IPV (REPEVAX®) can boost immunity against several diseases simultaneously. This Phase IIIb, parallel-group, open-label trial compared antibody responses to Tdap-IPV and tetanus monovalent vaccine (TMV; Vaccin Tétanique Pasteur® or Tetavax®...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.4161/hv.22083
更新日期:2012-12-01 00:00:00
abstract::Limited safety data are available on inadvertent exposure to quadrivalent human papillomavirus vaccine (4vHPV) during pregnancy. We conducted a descriptive observational postlicensure safety surveillance study in Kaiser Permanente Southern California and Northern California to assess congenital anomaly and miscarriage...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2017.1403702
更新日期:2018-02-01 00:00:00
abstract::Vaccination directly protects vaccinated individuals, but it also has the potential for indirectly protecting the unvaccinated in a population (herd protection). Unintended negative consequences such as the re-manifestation of infection, mainly expressed as age shifts, result from vaccination programs as well. We disc...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章,评审
doi:10.1080/21645515.2015.1052196
更新日期:2015-01-01 00:00:00
abstract::Human papillomavirus (HPV) vaccine uptake among 18-26 y old women varies by geographic region in the US. However, little is known about regional variations in vaccination among girls who are in the vaccine's targeted age groups. Regional variation in HPV vaccination among female adolescents (9-17 y old) was examined u...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.4161/21645515.2014.980202
更新日期:2014-01-01 00:00:00
abstract::The currently available drugs to treat hepatitis B virus (HBV) infection include interferons and nucleos(t)ide analogs, which can only induce disease remission and are inefficient for the functional cure of patients with chronic HBV infection (CHB). Since high titers of circulating hepatitis B surface antigen (HBsAg) ...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2017.1319021
更新日期:2017-08-03 00:00:00
abstract::Attenuated measles virus (MV) is one of the most effective and safe vaccines available, making it attractive candidate vector to prevent infectious diseases. Attenuated MV have acquired the ability to use the complement regulator CD46 as a major receptor to mediate virus entry and intercellular fusion. Therefore, atte...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章,评审
doi:10.1080/21645515.2015.1122146
更新日期:2016-05-03 00:00:00
abstract::Adjuvants produce complex, but often subtle, effects on vaccine-induced immune responses that, nonetheless, play a critical role in vaccine efficacy. In-depth profiling of vaccine-induced cytokine, cellular, and antibody responses ("immunoprofiling") combined with machine-learning holds the promise of identifying adju...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2019.1654807
更新日期:2020-01-01 00:00:00
abstract::Although catch-up campaigns (CCs) at the introduction of pneumococcal conjugate vaccines (PCVs) may accelerate their impact, supply constraints may limit their benefit if the need for additional PCV doses results in introduction delay. We studied the impact of PCV13 introduction with and without CC in Nha Trang, Vietn...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2018.1467201
更新日期:2018-01-01 00:00:00
abstract::If distributed equitably, Human Papillomavirus (HPV) vaccines have the potential to reduce racial disparities in HPV-related diseases and cervical cancers. However, current trends in the US indicate low uptake among all adolescents, with persistent disparities among minority and low-income adolescents despite largely ...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章,评审
doi:10.4161/hv.24422
更新日期:2013-07-01 00:00:00
abstract::Most influenza vaccines in Mexico are trivalent, containing two influenza A strains and a single B strain. Quadrivalent influenza vaccines (QIVs) extend protection by including an additional B strain to cover both co-circulating B lineages. Here, we retrospectively estimated how a switch to QIV in Mexico would have im...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2019.1678997
更新日期:2020-04-02 00:00:00
abstract::Anflu® is a seasonal trivalent inactivated split-virion influenza vaccine manufactured by Sinovac Biotech Co., Ltd. The objectives of this study were to evaluate the safety of Anflu® (2013-14 formulation: H1N1, H3N2 and BYAM) in infants and adults and its immunogenicity and cross-reactivity against mismatched influenz...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2015.1123357
更新日期:2016-05-03 00:00:00
abstract::Timely vaccine supply is critical during influenza pandemics but is impeded by current virus-based manufacturing methods. The 2009 H1N1/2009pdm 'swine flu' pandemic reinforced the need for innovation in pandemic vaccine design. We report on insights gained during rapid development of a pandemic vaccine based on recomb...
journal_title:Human vaccines & immunotherapeutics
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1080/21645515.2017.1279765
更新日期:2017-06-03 00:00:00
abstract::The aim of this Phase IIIb, open-label, randomized study was to demonstrate the non-inferiority of immune responses and to assess the safety of a purified chick-embryo cell rabies vaccine (PCECV) in healthy Chinese children (6 to 17 years) and older adults (≥51 years) following 2 alternative intramuscular (IM) simulat...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章,随机对照试验
doi:10.4161/21645515.2014.994460
更新日期:2015-01-01 00:00:00
abstract::Leukemia-associated antigens such as proteinase-3 (PR3) and Wilms' tumor protein-1 (WT-1) are potential targets of T-cell responses, which can be monitored by T-cell assays within vaccination trials and after allogeneic stem cell transplantation (SCT). In chronic myeloid leukemia (CML) an aberrant cytokine profile of ...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.4161/hv.24250
更新日期:2013-06-01 00:00:00
abstract::Pandemic outbreaks of influenza type A viruses have resulted in numerous fatalities around the globe. Since the conventional influenza vaccines (CIV) provide less than 20% protection for individuals with weak immune system, it has been considered that broadly cross-neutralizing antibodies may provide a better protecti...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2017.1403703
更新日期:2018-02-01 00:00:00
abstract::The objective of this analysis was to compare the anti-HPV GMTs and their distribution after a 6-month or a 3-8 -y interval between two HPV vaccine doses. The results from two clinical trials, conducted by the same team in the same region, with serological assays performed at the same laboratory using the same ELISA m...
journal_title:Human vaccines & immunotherapeutics
pub_type: 临床试验,杂志文章
doi:10.1080/21645515.2019.1605278
更新日期:2019-01-01 00:00:00
abstract::Since 2006, some Italian Regions introduced the active offer of measles, mumps, rubella, and varicella (MMRV) vaccine for all newborns during the second years of life. In 2011, Italian Drug Authority (AIFA) recommended the discontinuation of the MMRV use for an increased risk of febrile seizures following vaccination;...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2019.1704124
更新日期:2020-08-02 00:00:00
abstract:BACKGROUND:Many low- to middle-income countries have completed or are in the process of transitioning from high or intermediate to low endemicity for hepatitis A virus (HAV). Because the risk of severe hepatitis A disease increases with age at infection, decreased incidence that leaves older children and adults suscept...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2017.1323158
更新日期:2017-08-03 00:00:00
abstract::Typhoid fever, caused by Salmonella enterica serovar Typhi (S. Typhi), is a major health problem particularly in developing countries. The available vaccines have certain limitations regarding their efficacy, and inability to induce an immune response especially in individuals under 2 years of age. Conjugate vaccines ...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.4161/hv.18350
更新日期:2012-02-01 00:00:00
abstract::Dengue is prevalent in the Asia-Pacific region. Participants of two immunogenicity and safety phase II studies conducted in Singapore and Vietnam (NCT0088089 and NCT00875524, respectively) were followed for up to four years after third vaccine dose of a recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TD...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章,随机对照试验
doi:10.1080/21645515.2019.1578595
更新日期:2019-01-01 00:00:00